GLP-1 Cost in India (2026): রোগী আসলে কত দেন
Cost often Indian family GLP-1 deciding factor। city, pharmacy, molecule, innovator vs CDSCO generic semaglutide price vary। guide realistic 2026 expense hidden cost insurer ignore, titration budget, employer benefit limitation doctor plan, CDSCO warned misleading online deal chase নয়। sustainable therapy honest maths: first month titration dose নয়, first prescription-এর আগে monthly quote × 24।
Short answer
India GLP-1 RA typically ₹8,000–₹25,000/মাস out of pocket—molecule, dose, innovator vs CDSCO generic, city। most insurance obesity cover নয়। RSSDI type 2 diabetes clinical use support, reimbursement limited। lab, consultation, 12–24 month therapy budget। licensed pharmacy quote compare। Kesho cost education only—sell/negotiate নয়। start-এর আগে monthly quote × 24।
Key takeaways
- •২০২৬ most GLP-1 therapy ₹8,000–₹25,000 monthly out of pocket unless employer plan coverage confirm।
- •CDSCO-approved generic semaglutide licensed pharmacy-তে innovator-এর চেয়ে 20–40% cost reduce।
- •Titration lower dose months maintenance-এর চেয়ে কম—minimum 12–24 month budget, first prescription only নয়।
- •Hidden cost consultation, lab, dietitian, cold-chain travel, sharps disposal—often quarterly ₹2,000–₹5,000।
- •Prescription ছাড়া steep online discount CDSCO-flagged counterfeit/improper storage red flag।
- •Long-term GLP-1 commit-এর আগে realistic maintenance monthly quote × 24 months।
India-তে GLP-1 therapy expensive কেন?
GLP-1 RA relatively new patent-protected/recently off-patent biologic-class complex manufacturing cold-chain rigorous QC। metformin few hundred monthly vs weekly injectable pen device sterile production research cost insurance not cover consumer pass। India vast majority out of pocket public/private insurer obesity pharmacotherapy rarely reimburse diabetes GLP-1 limited select corporate policy। context realistic expectation: significant monthly commitment years diabetes/long-term weight maintenance। early budget treatment interruption glycaemic rebound weight regain prevent। RSSDI type 2 diabetes clinical value recognise guideline support automatic insurance payment নয়—gap explicitly plan।
২০২৬ molecule অনুযায়ী typical GLP-1 price range?
Exact price fluctuate 2025–2026 Indian pharmacy survey licensed retailer prescription maintenance dose approximate monthly: semaglutide injection weekly ₹8,000–₹18,000 dose product; oral semaglutide ₹10,000–₹20,000; tirzepatide ₹15,000–₹25,000; liraglutide daily ₹6,000–₹12,000; dulaglutide semaglutide similar band। metro sometimes tier-2 higher online competition narrow gap। final invoice GST correct strength pen number confirm month। CDSCO generic semaglutide range lower end available।
Approximate monthly GLP-1 costs (India, 2026)
- Medicine class: Semaglutide injection — Typical monthly (INR): ₹8,000 – ₹18,000 — Notes: Dose/product dependent
- Medicine class: Oral semaglutide — Typical monthly (INR): ₹10,000 – ₹20,000 — Notes: Daily tablet; strict timing
- Medicine class: Tirzepatide — Typical monthly (INR): ₹15,000 – ₹25,000 — Notes: Dual GIP/GLP-1 agonist
- Medicine class: Generic semaglutide — Typical monthly (INR): ₹6,000 – ₹14,000 — Notes: CDSCO-approved only
- Medicine class: Liraglutide (daily) — Typical monthly (INR): ₹6,000 – ₹12,000 — Notes: Older GLP-1 RA
First-year GLP-1 budget planner (estimated)
- Expense: Medication only — Low/year (INR): ₹72,000 — High/year (INR): ₹3,00,000
- Expense: Doctor consultations (quarterly) — Low/year (INR): ₹3,200 — High/year (INR): ₹10,000
- Expense: Laboratory tests — Low/year (INR): ₹2,000 — High/year (INR): ₹8,000
- Expense: Dietitian/support — Low/year (INR): ₹2,000 — High/year (INR): ₹12,000
- Expense: Travel, storage, supplies — Low/year (INR): ₹1,000 — High/year (INR): ₹5,000
- Expense: Total first-year — Low/year (INR): ₹80,200 — High/year (INR): ₹3,35,000
Generic semaglutide India cost কীভাবে change?
Patent expiry Indian manufacturer CDSCO-approved generic launch lower price sometimes 20–40% below innovator। generic same bioequivalence quality branded। generic consider CDSCO Central Licensing Authority portal approval manufacturer reputation storage verify। unverified online extremely low price counterfeit/improper storage red flag। diabetologist generic name prescription pharmacists local regulation substitute consent। savings multi-year therapy compromised quality clinical benefit safety negate negates। ICMR RSSDI innovator vs generic prefer না both CDSCO-approved same molecule। itemised receipt product name strength month-over-month compare।
City ও purchase channel-এ GLP-1 price differ?
Yes modestly। Mumbai Delhi premium ₹500–₹2,000/month tier-2 same CDSCO product। hospital OPD pharmacy standalone sometimes more cold-chain confidence। online licensed promotion injectable temperature-controlled delivery packaging confirm arrival। Hyderabad Chennai Pune corporate hospital generic semaglutide stock competition improve। rural cold-chain-capable pharmacy travel cost। unlicensed messaging-app 50–70% discount never—CDSCO advisory target channels।
Patient often overlook hidden cost?
Pen/tablet beyond endocrinologist consultation ₹800–₹2,500 private quarterly HbA1c lipid ₹500–₹2,000 occasional thyroid kidney dietitian ₹500–₹1,500 cold-chain pharmacy travel। nausea anti-emetic adjusted meal। sharps container inexpensive necessary। summer load-shedding refrigeration backup practical। titration lower dose first two months slightly less maintenance—one pen at a time titration ask pharmacy। corporate employee quarterly follow-up leave time account।
GLP-1 therapy vs other obesity interventions (cost view)
- Intervention: GLP-1 pharmacotherapy — Upfront: Low (first Rx) — Monthly: ₹8,000–₹25,000 — Notes: Schedule H; CDSCO only
- Intervention: Structured lifestyle — Upfront: ₹2,000–₹15,000 — Monthly: ₹500–₹3,000 — Notes: ICMR first-line obesity
- Intervention: Bariatric surgery — Upfront: ₹2,50,000–₹5,00,000+ — Monthly: Supplements, follow-up — Notes: One-time surgical
- Intervention: Metformin (off-label weight) — Upfront: Low — Monthly: ₹100–₹500 — Notes: Not primary obesity drug
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026